Open AccessClinical Utility of Pharmacogene Panel‐Based Testing in Patients Undergoing Percutaneous Coronary Intervention
Author(s) -
El Rouby Nihal,
Alrwisan Adel,
Langaee Taimour,
Lipori Gloria,
Angiolillo Dominick J,
Franchi Francesco,
Riva Alberto,
Elsey Amanda,
Johnson Julie A.,
Cavallari Larisa H.,
Winterstein Almut G.
Publication year - 2020
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12729
Subject(s) - conventional pci , percutaneous coronary intervention , medicine , pharmacogenetics , incidence (geometry) , genotype , emergency medicine , myocardial infarction , biochemistry , chemistry , physics , optics , gene
We aimed to estimate the utility of panel‐based pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI). Utilization of Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B drugs after PCI was estimated in a national sample of IBM MarketScan beneficiaries. Genotype data from University of Florida (UF) patients ( n = 211) who underwent PCI were used to project genotype‐guided opportunities among MarketScan beneficiaries with at least one ( N = 105,547) and five ( N = 12,462) years of follow‐up data. The actual incidence of genotype‐guided prescribing opportunities was determined among UF patients. In MarketScan, 50.0% (52,799/105,547) over 1 year and 68.0% (8,473/12,462) over 5 years had ≥ 1 CPIC A/B drug besides antiplatelet therapy prescribed, with a projected incidence of genotype‐guided prescribing opportunities of 39% at 1 year and 52% at 5 years. Genotype‐guided prescribing opportunities occurred in 32% of UF patients. Projected and actual incidence of genotype‐guided opportunities among two cohorts supports the utility of panel‐based testing among patients who underwent PCI.